Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$6.70
-6.0%
$11.61
$6.53
▼
$24.27
$387.41M0.753.35 million shs1.58 million shs
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$1.79
-2.2%
$2.61
$1.73
▼
$7.61
$109.73M3.22750,003 shs529,089 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$21.04
+4.8%
$22.71
$16.77
▼
$39.53
$400.56M3.51185,735 shs169,436 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-6.03%-21.27%-42.19%-66.20%-62.78%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-2.19%-14.35%-4.28%-74.47%-64.34%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%+9.73%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
+4.78%-4.19%-0.52%-41.64%+15.10%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$6.70
-6.0%
$11.61
$6.53
▼
$24.27
$387.41M0.753.35 million shs1.58 million shs
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$1.79
-2.2%
$2.61
$1.73
▼
$7.61
$109.73M3.22750,003 shs529,089 shs
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$17.42
$17.42
$14.50
▼
$19.92
$424.04M1.1518,480 shsN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$21.04
+4.8%
$22.71
$16.77
▼
$39.53
$400.56M3.51185,735 shs169,436 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-6.03%-21.27%-42.19%-66.20%-62.78%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-2.19%-14.35%-4.28%-74.47%-64.34%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.00%0.00%0.00%0.00%+9.73%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
+4.78%-4.19%-0.52%-41.64%+15.10%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
2.71
Moderate Buy$36.82449.53% Upside
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
2.27
Hold$6.14243.18% Upside
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
1.00
SellN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
2.80
Moderate Buy$69.17228.74% Upside

Current Analyst Ratings Breakdown

Latest FHTX, AVTX, PRTC, and TECX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
UpgradeSell (D-) ➝ Sell (D+)
11/6/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Lower Price TargetOutperform$22.00 ➝ $20.00
11/4/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated RatingSell (D-)
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Set Price Target$16.00
10/26/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated RatingOutperform
10/23/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Lower Price TargetOutperform$34.00 ➝ $22.00
10/23/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Lower Price TargetBuy$10.00
10/23/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
DowngradeBuy ➝ Neutral
10/23/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
DowngradeBuy ➝ Neutral
10/16/2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
Reiterated RatingBuy
10/15/2026
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
Reiterated RatingSell (D-)
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
$59K6,566.34N/AN/A$7.55 per share0.89
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
$112.13M0.96N/AN/A($0.23) per share-7.78
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
$4.66M91.01N/AN/A$12.65 per share1.38
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/A$11.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$78.26M-$2.52N/AN/AN/AN/A-34.21%-29.84%N/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$74.28M$0.0725.58N/AN/A8.40%-13.46%4.63%N/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
-$109.74MN/AN/AN/AN/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$74.15M-$4.63N/AN/AN/AN/A-37.69%-35.65%N/A

Latest FHTX, AVTX, PRTC, and TECX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
-$0.2356$0.80+$1.0356$0.80$7.10 million$83.54 million
11/5/2026Q3 2026
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
-$0.5883-$0.34+$0.2483-$0.34N/AN/A
11/5/2026Q3 2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$1.32-$1.08+$0.24-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/AN/AN/AN/AN/A
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/AN/AN/AN/AN/A
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
N/A
16.63
16.63
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
N/A
4.24
4.24
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
N/A
6.59
6.59
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/A
19.71
19.71

Institutional Ownership

CompanyInstitutional Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
87.06%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
61.55%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
0.04%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
62.63%

Insider Ownership

CompanyInsider Ownership
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
4.46%
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
9.02%
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
5.30%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
39.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avalo Therapeutics, Inc. stock logo
AVTX
Avalo Therapeutics
3357.82 million55.24 millionOptionable
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
10659.96 million54.55 millionOptionable
PureTech Health PLC Sponsored ADR stock logo
PRTC
PureTech Health
10024.34 million23.05 millionNot Optionable
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
6019.95 million12.01 millionOptionable

Recent News About These Companies

Tectonic Therapeutic Inc
Tectonic Therapeutic Inc TECX

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avalo Therapeutics stock logo

Avalo Therapeutics NASDAQ:AVTX

$6.70 -0.43 (-6.03%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$6.82 +0.12 (+1.79%)
As of 07:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Foghorn Therapeutics stock logo

Foghorn Therapeutics NASDAQ:FHTX

$1.79 -0.04 (-2.19%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.79 0.00 (0.00%)
As of 11/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

PureTech Health stock logo

PureTech Health NASDAQ:PRTC

$17.42 0.00 (0.00%)
As of 11/6/2026

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Tectonic Therapeutic stock logo

Tectonic Therapeutic NASDAQ:TECX

$21.04 +0.96 (+4.78%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$21.46 +0.41 (+1.97%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.